Ameliorative Effects of Ellagic Acid on Maximal Electroshock and Pentylenetetrazole-Induced Seizures in Mice

Ahad Khazaei, Seyyed Mohammad Taghi Mansouri, Amir Siahpoosh, Behnam Ghorbanzadeh, Saeed Salehi, and Mohammad Javad Khodayar

1Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2Department of Anesthesiology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA
3Department of Pharmacognosy, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4Department of Pharmacology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
5Toxicology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
6Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Toxicology, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: jkhodayar@yahoo.com

Received 2015 June 15; Revised 2018 June 01; Accepted 2018 September 29.

Abstract

Background: Epilepsy is a series of disorders in the central nervous system defined by disruption and abnormality in the electrical activity of the brain. The mechanisms of epilepsy occurrence are not fully determined and the current pharmacological therapeutics have low efficacy and are associated with adverse reactions due to narrow therapeutic indices. Ellagic acid has neuroprotective and antioxidant effects and increases the brain’s GABA levels.

Objectives: This study was designed to evaluate the effects of ellagic acid on both maximal electroshock and pentylenetetrazole models of acute seizures in mice.

Methods: Ellagic acid was administered at the doses of 25, 50, and 100 mg/kg in the two models of seizures.

Results: The results showed that ellagic acid was effective at the lowest dose in the maximal electroshock-induced seizure in mice and the duration of hind limb tonic extension (HLTE) was significantly shorter in this group than in the untreated convulsive group. In the pentylenetetrazole convulsion model, ellagic acid significantly increased the latency to convulsion and Straub tail response. The latencies with ellagic acid were longer in groups treated with ellagic acid 25 mg/kg than with ellagic acid 50 and 100 mg/kg.

Conclusions: In conclusion, it seems that ellagic acid has anticonvulsant effects in electroshock and pentylenetetrazole models of convulsion but its effects are attenuated or eliminated at higher doses.

Keywords: Ellagic Acid, Pentylenetetrazole, Maximal Electroshock, Seizure, Mice

1. Background

Epilepsy is the most common disorder of the central nervous system. It occurs due to the disruption of electrical activity, leading to acute and chronic changes in nerve function and mental abnormality (1). Epidemiologic studies show that 1% of people worldwide are affected by epilepsy and its prevalence is two to three times higher in African countries than in the rest of the world (2). In developed countries, there are 4 to 10 people with epilepsy per 10000 population (3). There is a relationship between the epilepsy prevalence and age so that it is more common in the first 10 years of life, especially in the first year (4). The abnormal discharge of nerve cells by various factors such as low blood sugar, oxygen deficiency, and infection makes imbalance between excitatory and inhibitory systems in the brain and leads to convulsion and the loss of consciousness (5).

In the last decade, plants have found an important role in clinical application as natural resources of pharmaceutical products. Nowadays different types of herbal medicines are commercially available in various dosage forms in the market (6). The World Health Organization estimates that 80% of populations in Asian and African countries use traditional medicine for the remedy of disease (7). Ellagitannins are hydrolyzable tannins that have functions in cell membranes (8). When ellagitannins are exposed to acid or base, the ester bond is hydrolyzed to form ellagic acid as a gallic acid dimer (Figure 1).

Ellagic acid is found in plants such as pomegranate, walnut, strawberry, blueberry, eucalyptus, and oak (9). Because of the key role of these compounds in the treatment of cancer and cardiovascular diseases, they are considered
as useful compounds in the human diet. Several studies confirmed that these effects are attributed to their antioxidant activity (10). Ellagitannins have antidepressant, anti-inflammatory, and analgesic properties, as well (11-13). Several studies showed that ellagic acid is useful for the treatment of colitis, Alzheimer’s disease, Parkinson’s disease, and anxiety and it can reduce the symptoms of nicotine dependence (14-18). In addition, ellagic acid has a protective effect on liver toxicity induced by carbon tetrachloride (19). It has been shown that ellagic acid considerably increases the activity of glutathione S-transferase and glutathione levels in cancer cells (20). Ellagic acid can make increases in the activity or induction of genes involved in the expression of superoxide dismutase, catalase, and NADPH quinones oxidoreductase and it has a neuroprotective effect on neurons against oxidative damage (21). As previously reported, ellagic acid has neuroprotective and antioxidant effects and increases the brain’s GABA levels and GABAergic transmission (22).

2. Objectives

This study was designed to evaluate and compare the effects of ellagic acid on two models of seizures in mice including maximal electroshock (MES)-induced convulsion for grand mal epilepsy and pentylenetetrazole (PTZ)-induced seizure for absence epilepsy.

3. Methods

3.1. Experimental Animals

C57 albino mice in the weight range of 23 ± 3 g were purchased from the Research Center and Experimental Animal House of Ahvaz Jundishapur University of Medical Sciences (AJUMS). The mice were kept in standard cages at 23 ± 2°C under a 12-hour light/dark cycle. All animals had free access to food and water throughout the experiment and benefited from the diet and adequate water because dehydration and lack of adequate food could change the seizure threshold (23). The experiments were carried out at a certain time of day (10 a.m. to 14 p.m.). For adaptation to the environment and elimination of anxiety, the animals were put in the experiment place 30 minutes before the experiments started. The study was approved by the Ethics Committee of AJUMS for Care and Use of Laboratory Animals.

3.2. Drugs and Chemicals

Ellagic acid and PTZ (Sigma-Aldrich, USA), diazepam ampoule (Caspian Pharmaceutical Co., Iran), phenytoin ampoule (Caspian Pharmaceutical Co., Iran), and carboxymethyl cellulose (CMC) (Merck, Germany) were purchased for research in this study. Ellagic acid was suspended in normal saline and CMC 0.1% and stored at 4°C.

3.3. Selection of Doses

The approved dose of ellagic acid with no side effects in animal models is 778 mg/kg. However, based on a pilot study, ellagic acid was used at the doses of 25, 50, and 100 mg/kg in the current study (12). In addition, PTZ at 85 mg/kg and diazepam at 1 mg/kg were applied (23, 24).

3.4. Animal Models for Evaluation of Anticonvulsant Activity

3.4.1. Maximal Electroshock (MES) Seizure

In the mice model, MES seizure is often induced by an electric current of 50 mA and a frequency of 1500 Hz (21) for 0.2 second. However, the seizure intensity depends on the animal strain and the quality of the apparatus (25-27). In this study, the seizure was induced with an electric current of 50 mA at a frequency of 80 Hz for 0.2 second.

3.4.2. Pentylenetetrazole (PTZ)-Induced Seizure

The convulsant doses of PTZ are between 85 and 150 mg/kg in mice. Thus, we needed first to determine the minimum required dose for seizure induction (28). In this study, PTZ was used at a dose of 85 mg/kg for seizure induction.

3.5. Experimental Protocol

3.5.1. Groups for MES-Induced Convulsions

The MES-induced convulsion groups included Group 1 (control) receiving normal saline (NS, 10 mL/kg) intraperitoneally (i.p.), Group 2 receiving phenytoin injection (50 mg/kg i.p.), and Groups 3, 4, and 5 receiving ellagic acid (25, 50, and 100 mg/kg i.p., respectively). After 30 minutes, the electric shock was inserted to animals’ ears with...
the intensity of 50 mA and the frequency of 80 Hz for 0.2 second through two pegs soaked with salt water. Then, the symptoms of seizures were evaluated by measuring the percent protection and duration of hind limb tonic extension (HLTE). The HLTE was the duration of the legs stretched backward and gathered inside the body.

3.5.2. Groups for PTZ-Induced Convulsions
The PTZ-induced convulsion groups included Group 1 (control) receiving NS (10 mL/kg i.p.), Group 2 receiving diazepam (1 mg/kg, i.p.), and Groups 3, 4, and 5 receiving ellagic acid (25, 50, and 100 mg/kg i.p., respectively). After 30 minutes, PTZ (85 mg/kg, i.p.) was injected to mice and then the latency to convulsions and Straub tail response, myoclonic activity duration, and the rate of mortality were recorded.

3.6. Statistical Analysis
All results are expressed as means ± SEM. To compare the effects of different doses of ellagic acid on seizure, the one-way ANOVA followed by Tukey’s post hoc test was used. P values of < 0.05 were considered statistically significant.

4. Results
4.1. Effects of Ellagic Acid on MES-Induced Convulsions
As shown in Table 1, MES could induce seizures in the control and ellagic acid-treated groups while phenytoin prevented seizure in mice. The duration of HLTE was significantly different between the group treated with ellagic acid 25 mg/kg and the control group (P < 0.05). The increased dose of ellagic acid led to the longer duration of HLTE so that ellagic acid at the dose of 100 mg/kg could not prevent seizure. It seems that the higher doses of ellagic acid were not effective in the MES model of convulsion in mice.

4.2. Effects of Ellagic Acid on PTZ-Induced Convulsion
The results showed that PTZ could induce convulsion, which was associated with the decreased latency to convulsion and latency to Straub tail (Table 2); in addition, the duration of the myoclonic activity was significantly longer in this group than in the group treated with diazepam and ellagic acid. Ellagic acid effects on seizure were dose-dependent in reverse so that the latency to convulsion and latency to Straub tail were shorter in the group treated with ellagic acid 100 mg/kg than in the group treated with ellagic acid 25 mg/kg. These suggest that the anticonvulsant effects of ellagic acid decreased with increasing dose. Furthermore, ellagic acid 25 mg/kg resulted in the decreased duration of myoclonic activity, but this reduction was not statistically significant. Ellagic acid also led to a reduction in mortality rate (3/6, 2/6, and 2/6 in groups treated with ellagic acid 25, 50, and 100 mg/kg, respectively). Diazepam (1 mg/kg, i.p.) failed to show any convulsive activity in mice.

5. Discussion
Ellagic acid is a polyphenol with antioxidant properties. This compound is found in fruits such as pomegranate (29). Maximal electroshock (MES) is a model for the induction of generalized seizures of the tonic-clonic (grand mal) type. In this model, seizures are induced in animals by the electric current (27, 30). Recent reports have declared that MES represents a good model to study the early stages of epilepsy (31). The sudden discharge of neurons by the electric current occurs once the animal goes to the phase of HTLE and then returns to the initial state or dies. If the electric current is not adequate to create HTLE or the animal is protected by a drug, the animal will not enter this phase (32). In this study, the effect of ellagic acid was evaluated on the HTLE time. The results showed that only were mice in the group treated with ellagic acid 25 mg/kg protected against electroshock. The protective effects of orally administered ellagic acid on different models of seizure have been reported in the literature (22). Absence seizure occurs due to interferences in the function of GABA made by GABA_A receptor agonists (33), similar to the one that occurs in the animal model of seizure induced by PTZ. Our results showed that the duration of myoclonic activity was not significantly different between groups treated with different doses of ellagic acid and the untreated control group. Nevertheless, the beneficial effects of ellagic

| Group | Dose | HTLE Duration (s) |
|-------|------|------------------|
| Control | 10 mL/kg, i.p. NS | 18.90 ± 0.91 |
| Phenytoin | 25 mg/kg, i.p. | 0 ± 0 |
| EA 25 | 25 mg/kg, i.p. | 16.59 ± 1.05d |
| EA 50 | 50 mg/kg, i.p. | 17.38 ± 1.86 |
| EA 100 | 100 mg/kg, i.p. | 17.21 ± 0.88 |

Abbreviations: EA25, ellagic acid 25 mg/kg; EA50, ellagic acid 50 mg/kg; EA100, ellagic acid 100 mg/kg; NS, normal saline.

 dengan 0.05 as compared to MES-induced convulsion control mice.

| a | b | c | d |
|---|---|---|---|
| Data were analyzed by the one-way ANOVA followed by Tukey's HSD multiple comparison test. |
| N = 6 in each group. |
| Values are presented as means ± SEM. |
| P < 0.05 as compared to MES-induced convulsion control mice. |
Ellagic acid is known to act as a ligand for GABA_A receptors and exhibit anticonvulsant effects (35-37). The anticonvulsant properties of ellagic acid could inhibit the formation of reactive oxygen species (ROS) in the brain (43, 44). This supports that ellagic acid may be exerted through decreasing oxidative stress and increasing GABA_A transmission in the brain.

### Acknowledgments

This paper is derived from a Pharm-D. thesis by Ahad Khazaei and supported by the Medicinal Plants Research Center (grant number: MPRC-068), funded by the Vice Chancellor for Research, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

### Footnotes

**Conflict of Interests:** The authors report no conflicts of interest in this study.
Ethical Approval: The study was approved by Ethical Committee Acts of AJUMS for care and use of laboratory animals.

Funding/Support: It is not declared by the authors.

References

1. Raviglione MC, O’Brien RJ, Kasper D, Braunwald E, Fauci A, Hauser S, et al. Harrison's principles of internal medicine. 2005.
2. Preux P, Druet-Cabanac M. Epidemiology and aetiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 2005;4(1):21-31. doi: 10.1016/S1474-4422(04)00963-9. [PubMed: 15620854].
3. Bradley WG, Daroff RB, Fenichel GM, Jankovic J. Diagnosis of neurological disease. Neurology in clinical practice: Principles of diagnosis and management. 2004.
4. Kostopoulos I, de Krom M, Kessels F, Lodder J, Troost J, Twellaar DM. The genotoxicity study of garlic and non-epileptic seizures. Seizure. 2005;14(6):375-82. doi: 10.1016/j.seizure.2005.01.005. [PubMed: 15797352].
5. Schindler K, Leung H, Elger CE, Lehnertz K. Assessing seizure dynamics by analysing the correlation structure of multichannel intracranial EEG. Brain. 2007;130(1 Pt 1):65-77. doi: 10.1093/brain/ajm304. [PubMed: 17082199].
6. Kalantari H, Lakri A, Latifi SM. The genotoxicity study of garlic and paspy herbal drops by peripheral blood micronucleus test. Acta Physiol Hung. 2007;94(3):261-6. doi: 10.1556/APhysiol.94.2007.3.10. [PubMed: 17853777].
7. Loscher W, Fassbender CP, Nolting B. Assessing seizure dynamics by analysing the correlation structure of multichannel intracranial EEG. Brain. 2007;130(1 Pt 1):65-77. doi: 10.1093/brain/ajm304. [PubMed: 17082199].
8. Larrosa M, Garcia-Conesa MT, Espin JC, Tomas-Barberan FA. Ellagitannins, ellagic acid and vascular health. Mol Aspects Med. 2010;31(6):513–49. doi: 10.1016/j.mam.2010.09.005. [PubMed: 20837052].
9. Sarkaki A, Farhood Y, Dolati M, Mansouri SMT, Khodadadi A. Neurprotective effects of ellagic acid in a rat model of Parkinson’s disease. Acta Medica Iranica. 2016;54(4):394-502.
10. Singh K, Khanna AK, Chander R. Hepatoprotective activity of ellagic acid against carbon tetrachloride induced hepatotoxicity in rats. Indian J Exp Biol. 1999;37(10):1025-6. [PubMed: 10783760].
11. Singh K, O’Brien RJ, Kasper D, Braunwald E, Fauci A, Hauser S, et al. Harrison's principles of internal medicine. 2005.
12. Marin M, Maria Giner R, Rios JL, Recio MC. Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J Ethnopharma- col. 2013;150(3):925-34. doi: 10.1016/j.jep.2013.09.030. [PubMed: 24405855].
13. Fang Y, Yang SG, Du XT, Zhang X, Sun XX, Zhao M, et al. Ellagic acid promotes Abeta42 fibrillation and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun. 2009;379(4):1250-4. doi: 10.1016/j.bbrc.2009.10.130. [PubMed: 19878655].
14. Perez-Pasten R, Artillan-Gil A, Zuniga-Perez C, Filardo-Kestrupp S, Otazo-Sanchez ME, Madrigal-Santillan O, et al. Ellagic acid reduced nicotine induced withdrawal syndrome in mice. Toxicology Letters. 2009;180(1-2):1-2. doi:10.1016/j.toxlet.2009.06.053.
15. Fang Y, Yang SG, Du XT, Zhang X, Sun XX, Zhao M, et al. Ellagic acid promotes Abeta42 fibrillation and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun. 2009;379(4):1250-4. doi: 10.1016/j.bbrc.2009.10.130. [PubMed: 19878655].
16. Perez-Pasten R, Artillan-Gil A, Zuniga-Perez C, Filardo-Kestrupp S, Otazo-Sanchez ME, Madrigal-Santillan O, et al. Ellagic acid reduced nicotine induced withdrawal syndrome in mice. Toxicology Letters. 2009;180(1-2):1-2. doi:10.1016/j.toxlet.2009.06.053.
17. Searrn NP, Adams IS, Henning SM, Niu Y, Zhang Y, Nair MG, et al. In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin quantification, and evaluation. J Nutr Biochem. 2005;16(6):360-7. doi: 10.1016/j.jnutbio.2005.01.006. [PubMed: 15936648].
18. Teel RW, Babcock MS, Dixit R, Stoner GD. Ellagic acid toxicity and interaction with benzo[a]pyrene and benzo[a]pyrene 7,8-dihydrodiol in human bronchial epithelial cells. Cell Biol Toxicol. 1986;2(1):53-62. [PubMed: 3267445].
19. Uzar E, Alp H, Cevik MU, Firat U, Eviyapoglu O, Tufek A, et al. Ellagic acid attenuates oxidative stress on brain and sciatic nerve and improves histopathology of brain in streptozotocin-induced diabetic rats. Neurosci Lett. 2012;513(1):57-64. doi: 10.1016/j.neulet.2011.07.075. [PubMed: 22922112].
20. Dhangra D, Jangra A. Antiepileptic activity of ellagic acid, a naturally occurring polyphenolic compound, in mice. Journal of Functional Foods. 2014;10:364-9. doi: 10.1016/j.jff.2014.07.011.
21. Albertson TL, Peterson SL. Neuropharmacology methods in epilepsy research. CRC press; 1998.
22. Ojewole JA. Analgesic and anticonvulsant properties of Tetrapleura tetraptera (Taubi) [Fabaceae] fruit aqueous extract in mice. Phytother Res. 2005;19(12):1023-9. doi: 10.1002/ptr.1779. [PubMed: 16372367].
23. Preuda SG, Woodhead JH, Swinyard EA. Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate. J Pharmocol Exp Ther. 1985;232(3):741-5. doi: 10.1124/jpet.1985.232.3.741. [PubMed: 3199774].
24. Swinyard EA, Kuperberg HJ, editors. Antiepileptic drugs: Detection, quantification, and evaluation. Federation proceedings, 1985. p. 2626-33.
25. Loscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsia. 1988;29(3):145-81. [PubMed: 3058469].
26. Reddy DS, Rogawski MA. Stress-induced deoxycoformecosterone-derived neurosteroids modulate GABA(A) receptor function and seizure susceptibility. J Neurosci. 2002;22(9):3795-805. [PubMed: 11978855].
27. Yoshimura M, Watanabe Y, Kasi A, Yamakoshi J, Koga T. Inhibitory effect of an ellagic acid-rich pomegranate extract on tyrosine activity and ultraviolet-induced pigmentation. Biosci Biotechnol Biochem. 2005;69(2):2368-73. doi: 10.1271/bbb.69.2368. [PubMed: 1637795].
28. White HS. Preclinical development of antiepileptic drugs: Past, present, and future directions. Epilepsia. 2003;44 Suppl 7:2-8. doi: 10.1111/j.1528-1167.2003.01912.x. [PubMed: 12991912].
29. Rogawski MA. Molecular targets versus models for new antiepileptic drug discovery. Epilepsy Res. 2006;68(1):228-32. doi: 10.1016/j.eplepsia.2005.09.012. [PubMed: 1637751]. [PubMed Central PMCID:3173807].
30. Castel-Branco MM, Alves GL, Figueiredo IV, Falcao AC, Caramona MM. The maximal electroshock seizure (MES) model in the preclinical assessment of potential new antiepileptic drugs. Methods Find Exp Clin Pharmacol. 2009;31(2):106-10. doi:10.1177/1070394X093313841. [PubMed: 19452655].
33. Han HA, Cortez MA, Carter Snead Iii O. GABAB receptors in absence epilepsy. *Epilepsia*. 2010;51:24. doi: 10.1111/j.1528-1167.2010.02810.x.

34. Jager AK, Saaby L. Flavonoids and the CNS. *Molecules*. 2011;16(2):1471-85. doi: 10.3390/molecules16021471. [PubMed: 21311414]. [PubMed Central: PMC6259921].

35. Nassiri-Asl M, Shariati-Rad S, Zamansoltani F. Anticonvulsive effects of intracerebroventricular administration of rutin in rats. *Prog Neuropsychopharmacol Biol Psychiatry*. 2008;32(4):989–93. doi: 10.1016/j.pnpbp.2008.01.001. [PubMed: 18262708].

36. Abbasi E, Nassiri-Asl M, Shafeei M, Sheikhi M. Neuroprotective effects of vitexin, a flavonoid, on pentylenetetrazole-induced seizure in rats. *Chem Biol Drug Des*. 2012;80(2):274-8. doi: 10.1111/j.1747-0285.2012.01400.x. [PubMed: 22554416].

37. Khodayar MJ, Salehi S, Rezaei M, Shahpoosh A, Khazaei A, Houshmand G. Evaluation of the effect of naringenin on pentylenetetrazole and maximal electroshock-induced convulsions in mice. *Jundishapur J Nat Pharm Prod*. 2016;12(1). doi: 10.5812/jjppp.3184.

38. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Calvo D, et al.Overview-flavonoids: A new family of benzodiazepine receptor ligands. *Neurochem Res*. 1997;22(4):419-25. [PubMed: 9102524].

39. Marder M, Paladini AC. GABA(A)-receptor ligands of flavonoid structure. *Curr Top Med Chem*. 2002;2(8):553-67. [PubMed: 12171576].

40. Khanduja KL, Gandhi RK, Pathania V, Syal N. Prevention of N-nitrosodiethylamine-induced lung tumorigenesis by ellagic acid and quercetin in mice. *Food Chem Toxicol*. 1999;37(4):313-8. [PubMed: 10418948].

41. Loarca-Pina G, Kuzmicky PA, de Mejia EG, Kado NY. Inhibitory effects of ellagic acid on the direct-acting mutagenicity of aflatoxin B1 in the Salmonella microsuspension assay. *Mutat Res*. 1998;398(1-2):183-7. doi: 10.1016/s0027-5107(97)00245-5. [PubMed: 9626978].

42. Geronzi U, Lotti F, Grosso S. Oxidative stress in epilepsy. *Expert Rev Neurother*. 2018;18(3):427-34. doi: 10.1080/14737175.2018.1465410. [PubMed: 29651885].

43. Singh N, Vijayanti S, Saha L, Bhatta A, Banerjee D, Chakrabarti A. Neuroprotective effect of Nrf2 activator dimethyl fumarate, on the hippocampal neurons in chemical kindling model in rat. *Epilepsy Res*. 2018;143:98-104. doi: 10.1016/j.eplepsyres.2018.02.001. [PubMed: 29691120].

44. Shin EJ, Jeong JH, Chung YH, Kim WK, Ko KH, Bach JH, et al. Role of oxidative stress in epileptic seizures. *Neurochem Int*. 2011;59(2):322-37. doi: 10.1016/j.neuint.2011.03.025. [PubMed: 21672578]. [PubMed Central: PMC3605555].

45. Yang CS, Tsou BC, Liu YP, Tsai MJ, Shyue SK, Tseng SF. Inhibition of cadmium-induced oxidative injury in rat primary astrocytes by the addition of antioxidants and the reduction of intracellular calcium. *J Cell Biochem*. 2008;103(3):825-34. doi: 10.1002/jcb.21452. [PubMed: 17616669].